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Abstract
Background Declarative memory deficits are common in
untreated adults with attention-deficit hyperactivity disorder
(ADHD), but limited evidence exists to support improve-
ment after treatment with methylphenidate. The objective of
this study was to examine the effects of methylphenidate on
memory functioning of adults with ADHD.
Methods Eighteen adults with ADHD who were clinical
responders to methylphenidate participated in this randomized
crossover trial. After 3 days of no treatment, patients received
in random order either their usual methylphenidate dose
(mean: 14.7 mg; range: 10–30 mg) or placebo, separated by a
6–7-day washout period. Patients performed an immediate
word recall test 1 h after treatment administration. Three hours
after intake, patients performed the second part of the memory
test (delayed word recall and a recognition test).
Results Delayed recognition and immediate recall was similar
on treatment and on placebo. Delayed word recall was
significantly better in the methylphenidate than in the placebo
condition (F1, 17=7.0, p<0.017). A significant correlation
was found between prestudy CES-D depression scores and
difference scores on delayed recall (r=0.602, p<0.008).
Conclusion Methylphenidate improves declarative memory
functioning in patients with ADHD. New studies should
further examine whether subclinical depressive symptoms
mediate the effect of methylphenidate on declarative
memory.
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Introduction
Working memory deficits in adult patients with attention-
deficit hyperactivity disorder (ADHD) are well documented.
Working memory is significantly impaired in untreated adults
with ADHD (Ross et al. 2000) and significantly improves
once treated with methylphenidate (Cooper et al. 2005,
Turner et al. 2005, Mehta et al. 2000a, Mehta et al. 2000b)
and in healthy adult volunteers (Elliott et al. 1997). In
contrast, much less research has been devoted to declarative
memory functioning.
Declarative memory is the ability to store and retrieve
facts, plans, or ideas frommemory. Declarative memory skills
are important in daily life and social interaction (e.g., Kordon
et al. 2006). The lives of ADHD patients are often
characterized by forgetting appointments, things to do, or
even taking their medication on time.
Results on the effects of methylphenidate on declarative
memory functioning are inconclusive. Whereas Camp-Bruno
and Herting (1994) reported significant memory improvement
in 48 healthy volunteers after administration of methylpheni-
date, Unrug et al. (1997) found no significant effect of
methylphenidate (20 mg) on memory functioning measured
using a word learning test in 12 healthy volunteers. In patients
with ADHD, Riordan et al. (1999) reported significant
memory improvement when treated with methylphenidate.
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Memory improvement was equal in patients with and without
comorbid depression.
Given the limited number of studies, their inconclusive
results, and the significant impact of declarative memory
deficits on daily life of ADHD patients, the purpose of the
present study was to examine declarative memory functioning
in adult ADHD patients treated with methylphenidate or
placebo. A standardized validated and reliable word learning
test was used (Van Loon-Vervoorn 1985, 1986) to test the
hypothesis that methylphenidate will significantly improve
declarative memory functioning.
Methods and materials
The study was conducted according to a double blind,
placebo-controlled, randomized, crossover design.
A detailed description of the diagnosis of patients can be
read elsewhere (Verster et al. 2008). Patients underwent a
standardized psychiatric evaluation using a semi-structured
diagnostic interview for the presence of ADHD and co-
morbid disorders both current and in childhood. Presence
and severity of current ADHD symptoms during the last
6 months were scored using the Dutch version of the DSM-
IV ADHD-rating scale (Kooij et al. 2005), complemented
with information from partner, parents, and childhood
school reports. A cutoff point of five of nine criteria was
set for adult diagnosis of ADHD (Biederman et al. 2000;
Kooij et al. 2005). At the start of this study, the diagnosis
was confirmed by assessing the severity of current ADHD
symptoms using the DSM-IV ADHD-rating scale (Kooij et
al. 2005) and the CAARS ADHD rating scale (Conners et
al. 1999). Severity of symptoms of anxiety and depression
was measured by the Spielberger State Trait Anxiety
Inventory (STAI) and the Center for Epidemiological Studies
Depression Scale (CES-D) (Spielberger 1983; Beekman et al.
1997). Most important inclusion criteria were having ADHD,
being adult (21–55 years old), and being considered as reliable
and mentally capable of adhering to the protocol. Exclusion
criteria included insensitivity to methylphenidate treatment, a
history or presence of alcohol or drug abuse, comorbid anxiety or
depression (determined by treating physician), and the use of
psychoactive medication known to affect cognitive performance.
Eighteen patients diagnosed with ADHD (combined
type) participated in the study. Prior to participation in the
study, patients were stable and effectively treated with
methylphenidate. Patients were considered as effectively
treated if they used a stable daily dose of methylphenidate,
did not experience adverse effects from the treatment, and
were considered to be a clinical responder by the treating.
To participate in this study, patients were asked to
voluntarily stop their treatment, starting 3 days before the
first test day (session 2) until the second test day (session 3).
Session 2 and session 3 were separated by 6 to 7 days without
treatment. On the first test day, immediate release methylphe-
nidate (patients' regular dosage) or placebo was administered.
On the second test day, the other treatment was administered.
Treatment was administered orally with 240 ml tap water,
1 h before performing the first part of the memory test
(learning and immediate word recall). Thereafter, patients
performed an on-the-road driving test; results are discussed
elsewhere (Verster et al. 2008). After the driving test, i.e., 3 h
after treatment intake, patients performed the second part of
the memory test (delayed word recall and recognition). If
applicable, a second treatment dose was administered
according to the patient's usual interval between the first
and second doses. This was done to mimic the naturalistic
situation in which some patients take a second dose of
methylphenidate, for example, 2 h after their first dose. All
treatments were capsules of identical shape, size, and color,
to allow double blind administration. After completion of the
study, subjects continued their regular treatment regimen
under supervision of their psychiatrists. Patients were not
paid for participation, but their travel expenses were
reimbursed. In case of withdrawal or discontinuation, a
patient was replaced. The Medical Ethical Committee of the
University Medical Center Utrecht approved the study
protocol. Written informed consent was obtained before
their inclusion in the study.
Word learning test
Before discontinuation of their medication, all patients were
trained on the memory test to become familiar with test
procedures. The word learning test (Dutch language
version) is a computerized and standardized test with high
internal consistency. Test–retest reliability for immediate
and delayed recall were 0.80 and 0.83, respectively (Van
Loon-Vervoorn 1986). The test consists of 12 parallel lists
of 15 monosyllabic meaningful nouns (immediate and
delayed recall), complemented with 15 distracter words in
the recognition test. During training and each test day,
different validated word lists were used (versions A and B
on test days). Correlation between versions A and B of the
word learning test was 0.72 (Van Loon-Vervoorn 1986). All
were frequently used Dutch words, with high imageability
(Van Loon-Vervoorn 1985), and having low association
with each other. Fifteen words were presented five times on
a computer display. After each presentation, patients had to
write down as many words as they could remember. The
highest trial score was a measure of immediate recall.
Thereafter, patients performed a driving test on a Dutch
highway (Verster et al. 2008). Two hours after immediate
recall, delayed recall was recorded. Patients had to write
down in 1 min all words they remembered. Finally, the
original list along with 15 distracter words was presented.
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Patients had to indicate by button press whether a presented
word was a member of the original list or not. Recognition
was expressed in recognition time (ms) and recognition
score (number of correct recognized words).
Statistical analysis
Statistical analyses were performed using the SPSS. Mean
and standard deviation (SD) were computed for each
parameter. The factor treatment (two levels: methylphendate
and placebo group) was tested for significance (p<0.05) by
using ANOVA for repeated measures. Period (test day 1, test
day 2), treatment order (placebo->methylphenidate,
methylphenidate->placebo) were tested separately by using
ANOVA for repeated measures. The Pearson r correlation
coefficient was computed for baseline demographics and
difference scores (methylphenidate–placebo) for each memory
test parameter. In case of significance (p<0.05), the variable
was included as covariate in the statistical analysis.
Sample size
Sample size estimation of 30 subjects was based on the
primary outcome of the driving test in order to obtain a
power of at least 90%. Slow enrollment caused an early
study termination after 18 patients were completed (Verster
et al. 2008).
Results
The effects of period and treatment order were not
significant and, therefore, were omitted in the presented
statistical analyses. Eighteen patients (11 men and seven
women) completed the study. Mean (SD) age was 38.3
(7.7) years old. All patients had combined-type ADHD.
Patient characteristics are summarized in Table 1.
Patients did not differ on immediate word recall,
recognition time, and recognition score when treated with
methylphenidate or placebo (see Fig. 1). However, delayed
word recall was significantly improved when treated with
methylphenidate relative to placebo (F1, 17=7.0, p<0.017,
observed power 0.706). Performance on the memory test
did not significantly differ on any outcome when comparing
results from the test day of methylphenidate with the training
session results (on that day, patients were on their regular
methylphenidate regimen).
None of the baseline measures correlated significantly with
drug response, except for the CES-D depression score, which
showed a significant correlation with difference scores on
delayed recall (r=0.602, p<0.008). Although depression was
not diagnosed or treated, in six patients, screening scores on
the CES-D exceeded the cut-off score of 16. When
introducing CES-D scores as covariate in the statistical
analysis, a significant interaction between CES-D and
difference scores on delayed recall was found (F1, 16=11.6,
p<0.004). The difference in delayed recall between methyl-
phenidate and placebo was no longer significant (F1, 16=2.0,
p<0.174).
Discussion
This study shows that delayed word recall is significantly
affected in untreated patients with ADHD. When taking
methylphenidate, scores on the delayed word recall test
significantly improve to levels comparable of healthy
subjects. In contrast, immediate recall and delayed recog-
nition are not impaired in untreated ADHD patients. This
suggests that encoding and consolidation of memory is
unaffected. Delayed word recall requires patients to write
down all words they remember on a piece of paper. In
contrast, the recognition test shows all words on a computer
screen, mixed with distracting words that were not learned
during immediate recall. The recognition test is therefore
much easier than delayed word recall. In sum, retrieval
without priming as in the recognition test is impaired in
untreated patients with ADHD.
Interpretation of the relationship between the baseline
depression score and treatment effect on delayed recall is
difficult, in particular because some items scored with the
CES-D also apply for ADHD. CES-D scores were obtained
during screening when patients were all treated with
methylphenidate. It should be taken into account that the
CES-D is a screening instrument that is not sufficient to
diagnose patients. Patients who participated in the current
trial were not diagnosed or treated for comorbid depression.
The positive correlation between the methylphenidate–
placebo difference and CES-D score seems to suggest that
methylphenidate is more effective in ADHD patients who
report more depression-like symptoms. However, there is
mixed scientific evidence on whether methylphenidate has a
positive effect on comorbid depression and its effects on
memory functioning or not (Riordan et al. 1999; Barrickman
et al. 1995; Wilens et al. 1995, 1996; Jones et al. 2008). To
answer this question, comorbid depression scores of the
current sample were of insufficient clinical concern to draw
firm conclusions, as only six patients exceeded the cut-off
score of the CES-D. Therefore, future studies should focus
on the impact of comorbid disorders such as depression,
anxiety, and substance abuse. These comorbid disorders are
common and, as evident from this study, may have a clear
influence on the efficacy of ADHD treatment and its
behavioral correlates.
A limitation of our study may be the focus on declarative
memory only, using a single word learning test rather than
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performing a battery of memory tests that also include other
memory functions such as working memory or digit span.
Future studies should confirm our findings in a larger sample
size, including different treatments such as atomoxetine, and
including patients with clinical relevant comorbid disorders
such as anxiety and depression.
Studies in untreated adult ADHD patients confirm our
findings by showing that declarative memory functioning is
significantly worse when compared to healthy controls. For
example, Holdnack et al. (1995) compared neuropsycho-
logical performance of 25 untreated adult ADHD patients
with 30 healthy controls. Verbal learning was significantly
worse in patients with ADHD. Seidman et al. (1998)
compared performance of 64 untreated adult ADHD
patients with healthy controls. Relative to control subjects,
patients with ADHD performed significantly worse on the
California Verbal Learning test. Impairment on the memory
test was significant on immediate word recall and delayed
word recall after 20 min. Johnson et al. (2001) compared
memory functioning of 56 untreated patients with ADHD
with 38 healthy controls. Patients with ADHD demonstrated
significant verbal and nonverbal memory deficits. Both
immediate recall and delayed recall (after 30 min) were
significantly impaired when compared to control subjects. Dige
andWik (2005) examined memory functioning in 48 untreated
adult ADHD patients. Compared to healthy controls, ADHD
patients scored significantly worse on the auditory Consonant
trigram test (verbal dual-task memory), the Benton Visual
Retention test (short-term memory), the Rey Auditory Verbal
Learning test (immediate and delayed recall, recognition), and
the modified Diagnosticum für Cerebralschädigung (visual
learning and long-term memory).
A possible explanation may be that methylphenidate
enhances the release of dopamine. In the brain, the
ventrolateral prefrontal cortex and hippocampal formation
are involved in encoding and retrieval (Buckner et al. 1995,
Schacter and Wagner 1999). Dopamine regulates activity in
these brain structures, as well as the communication
between them (Schacter and Wagner 1999, Li et al. 2003).
Hence, depletion of dopamine in untreated patients with
ADHD could result in retrieval problems by dysfunctioning of
the circuitry between the hippocampal formation and ventro-
lateral prefrontal cortex (Bertolino et al. 2006). Histamine
plays a key role in learning and memory processes as well. It
has therefore also been hypothesized that methylphenidate
increases histamine levels in the brain, activated by
dopaminergic mechanisms (Horner et al. 2007).
Although the mechanism behind these effects requires
further study, the current study showed a significant
improvement in declarative memory functioning after
administration of methylphenidate.
Fig. 1 Results of the Word Learning Test (WLT) Mean (SE) group
score after intake of methylphenidate and placebo for immediate word
recall, delayed word recall and recognition. *=p<0.05









STAI CESD Total daily
dose (mg)




Mean 64.7 13.8 15.2 28.9 48.1 15.6 54.0 28.4 14.7
SD 8.7 5.8 4.8 9.6 10.1 8.5 20.4 25.0 6.3
Median 67.0 14.5 17.0 31.5 48.0 14.0 50.0 16.5 15.0
Range 43–47 3–22 5–23 9–41 28–64 5–33 30–105 5–72 10–30
A detailed overview of individual patient characteristics is published elsewhere (Verster et al. 2008)
CAARS Connor Adult ADHD Rating Scales, ADHD attention-deficit hyperactivity disorder, DSM Diagnostic and Statistical Manual of Mental
Disorders, STAI Spielberger State Trait Anxiety Inventory, CES-D Center for Epidemiological Studies Depression Scale, SD standard deviation
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